All News

Reimbursement

First Person in Europe Commercially Treated with BioMarin’s ROCTAVIAN® for Severe Hemophilia A
31 August 2023
First Person in Europe Commercially Treated with BioMarin’s ROCTAVIAN® for Severe Hemophilia A
BioMarin's ROCTAVIAN gene therapy has
Ready for Market – How Do We Get ATMPs Over the Line in Europe?
12 May 2023
Ready for Market – How Do We Get ATMPs Over the Line in Europe?
Join us as a panel
Top 10 Events in Cell & Gene Therapy 2022
18 January 2023
Top 10 Events in Cell & Gene Therapy 2022
It’s day 1 of Advanced
The Most Expensive Gene Therapy Approved by the FDA at $3.5M for Hemophilia B
23 November 2022
The Most Expensive Gene Therapy Approved by the FDA at $3.5M for Hemophilia B
Late-stage clinical trial company CellVax
POPULAR NEWS ITEMS
Image
21 September 2023

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Image
20 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

Image
20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

bluebird bio’s Zynteglo Approved by the FDA for Beta-Thalassemia
24 August 2022
bluebird bio’s Zynteglo Approved by the FDA for Beta-Thalassemia
bluebird bio has announced that
Market Access and Reimbursement Q&A with AviadoBio CEO Lisa Deschamps
21 June 2022
Market Access and Reimbursement Q&A with AviadoBio CEO Lisa Deschamps
Lisa Deschamps, AviadoBio CEO and
Market Access and Reimbursement Q&A with Nicola Redfern
21 June 2022
Market Access and Reimbursement Q&A with Nicola Redfern
Phacilitate's Advanced Therapies Europe speaker
Market Access and Reimbursement Q&A with Vice President of Novartis, Tay Salimullah
21 June 2022
Market Access and Reimbursement Q&A with Vice President of Novartis, Tay Salimullah
Load more News
RECOMENDED TOPICS
Clinical Trials
Collaborations, Mergers & Acquisitions
Finance & Investment
Patient Access & Engagement
Regulatory & Standards
Reimbursement
Strategy
POPULAR NEWS ITEMS
Image

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Image

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

Image

The Cell & Gene Therapy Manufacturing Capacity Map